1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin
(
- Contribution to journal › Article
- 2008
-
Mark
Epidemiology and the initial presentation of autoimmune hepatitis type 1 in Sweden, a nationwide study
2008) 43rd Annual Meeting of the European Association for the Study of the Liver In Journal of Hepatology 48(Suppl. 2). p.331-332(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response
(
- Contribution to journal › Article
- 1998
-
Mark
GBV-C/HGV infection in hepatitis C virus-infected deferred Swedish blood donors
(
- Contribution to journal › Article
- 1996
-
Mark
Factors influencing the response to interferon therapy in chronic hepatitis C. Studies on viral genotype and induction of 2',5'-oligoadenylate synthetase in the liver and peripheral blood cells
(
- Contribution to journal › Article
- 1995
-
Mark
HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profile
(
- Contribution to journal › Article
-
Mark
Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection
(
- Contribution to journal › Article
- 1993
-
Mark
Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment
(
- Contribution to journal › Article
-
Mark
Second-generation hepatitis C Elisa antibody tests confirmed by the four-antigen recombinant immunoblot assay correlate well with hepatitis C viremia and chronic liver disease in Swedish blood donors
(
- Contribution to journal › Article
- 1991
-
Mark
Successful treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by inhibitory effect on the immune response?
(
- Contribution to journal › Article